Long‐acting beta2‐agonists vs placebo
Participants with one or more serious adverse event (non‐fatal) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in participants with one or more serious adverse event (non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
- Long‐acting beta₂‐agonists for chronic obstructive pulmonary disease 2013 · Cochrane Headline outcomes onlyOR 0.97 [0.83, 1.14]20 studies · 12446 participantsModerate